3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
64
Phase NA
20
Phase 1
20
Phase 1/2
13
Phase 3
6
Phase 4
3
Phase 2/3
2
Status
Recruiting
4
Unknown
2
Not yet recruiting
2
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
40
Neoplasms
36
Prostatic Neoplasms
32
Colorectal Neoplasms
22
Carcinoma, Non-Small-Cell Lung
22
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Neoplasm Metastasis
14
Polycystic Ovary Syndrome
13
Lung Neoplasms
13
Stomach Neoplasms
12
Multiple Myeloma
11
Carcinoma, Hepatocellular
11
Recurrence
10
Pancreatic Neoplasms
10
Urinary Bladder Neoplasms
9
Lymphoma
9
Leukemia
9
Myelodysplastic Syndromes
8
Motor Activity
8
Head and Neck Neoplasms
8
Liver Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Brain Neoplasms
7
Pain
6
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Interventions
cediranib
1
Gemcitabine
1
Cisplatin
1
Capecitabine
1
ARRY-334543
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Completed
×
Biliary Tract Neoplasms
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts
NCT00939848
2014-10-27
ABC-03
University College, London
Phase 2/3
Completed
124 enrolled